Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
Submitted by
admin
on October 6, 2021 - 10:53am
Source:
Motley Fool
News Tags:
Merck
Pfizer
antivirals
COVID-19
vaccines
Headline:
Merck May Beat Pfizer to the COVID Pill Market. Does It Matter?
snippet:
Merck’s investigational covid pill cut the risk of hospitalization or death by 50%.
Pfizer already dominates the vaccine market -- but aims to launch an oral treatment too.
Pfizer expects to report results from its investigational covid pill trial during the fourth quarter.
Do Not Allow Advertisers to Use My Personal information
